Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board
March 02 2020 - 8:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical
company committed to developing medicines that transform the lives
of people with rare neurological diseases, today announced the
appointment of Alexander Kolevzon, M.D., a leader in child and
adolescent psychiatry, to its Scientific Advisory Board (SAB).
“2020 is an important year at Ovid. We anticipate clinical data
across both our neurodevelopmental and rare epilepsy programs,
including from our pivotal Phase 3 NEPTUNE trial with OV101 in
Angelman syndrome; our Phase 2 ROCKET signal-finding trial with
OV101 in Fragile X syndrome; as well as our open-label Phase 2
ARCADE trial with OV935 in CDKL5 and Dup15Q syndrome; and the
double-blind, placebo-controlled Phase 2 ELEKTRA trial with OV935
in Lennox-Gastaux syndrome and Dravet syndrome,” said Amit Rakhit,
M.D., MBA, president and chief medical officer of Ovid
Therapeutics. “We welcome Dr. Kolevzon to our scientific advisory
board. He is a world-renowned expert in neurodevelopmental
disorders, and his experience and knowledge complement the
capabilities already embodied by our other scientific advisors.
Alex’s input and advice will be invaluable as we continue to
advance our pipeline.”
Dr. Kolevzon is a professor of psychiatry and pediatrics at
the Icahn School of Medicine at Mount Sinai. His research
focuses on understanding the neurobiology of autism and
related neurodevelopmental disorders, biomarker discovery and novel
therapeutics. He serves as the director of child and
adolescent psychiatry for the Mount Sinai Health System and
the clinical director of the Seaver Autism Center for Research and
Treatment at Mount Sinai, where he leads the experimental
therapeutics program conducting research that ranges from small
pilot trials to multi-centered pivotal studies. Additionally, Dr.
Kolevzon leads a national rare disease consortium dedicated to
understanding the natural history of Phelan-McDermid syndrome and
developing electrophysiological biomarkers for use in clinical
trials. Dr. Kolevzon is widely published and is an active teacher,
mentor and clinical supervisor. He received his M.D. from Tel
Aviv University and a B.A. in psychology from the University of
Wisconsin.
“I am very excited to work with the Ovid team and support their
efforts in taking a meaningful step forward in the development of
treatments for patients with rare neurological diseases,” said Dr.
Kolevzon. “I believe OV101 may become an important therapeutic
option for patients with neurodevelopmental disorders, and I am
honored to have this opportunity to advise on Ovid’s research and
development programs as part of the scientific advisory board.”
About Ovid Therapeutics Ovid Therapeutics
Inc. is a New York-based biopharmaceutical company using
its BoldMedicine® approach to develop medicines that transform
the lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing OV935
(soticlestat) in collaboration with Takeda Pharmaceutical
Company Limited for the potential treatment of rare developmental
and epileptic encephalopathies (DEE). For more information on
Ovid, please visit http://www.ovidrx.com/.
Forward-Looking Statements This press
release includes certain disclosures that contain “forward-looking
statements,” including, without limitation, statements regarding:
advancing and commercializing Ovid’s product candidates, progress,
timing, scope and the potential therapeutic benefits based on
results of clinical trials for Ovid’s product candidates; and the
anticipated reporting schedule of clinical data regarding Ovid’s
product candidates. You can identify forward-looking statements
because they contain words such as “will,” “believes” and
“expects.” Forward-looking statements are based on Ovid’s current
expectations and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that may differ materially from
those contemplated by the forward-looking statements, which are
neither statements of historical fact nor guarantees or assurances
of future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include the fact that initial data from clinical trials
may not be indicative, and are not guarantees, of the final results
of the clinical trials and are subject to the risk that one or more
of the clinical outcomes may materially change as patient
enrollment continues and/or more patient data become available.
Additional risks that could cause actual results to differ
materially from those in the forward-looking statements are set
forth in Ovid’s filings with the Securities and Exchange
Commission under the caption “Risk Factors”. Ovid assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Contacts
Investors and Media: Ovid Therapeutics Inc.
Investor Relations & Public Relations irpr@ovidrx.com
Or
Investors: Steve Klass Burns McClellan,
Inc. sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman 1AB
katie@1abmedia.com(919) 333-7722
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024